StockMacro
Menu

ICU Medical

$172.52 +28% in 6 monthsMarket cap $4.3B

ICUI on XNAS, Health Care, ICU Medical Inc, job postings

Measures activity, not value. Not investment advice.

Twelve-month revenue fell 5.9% to $2.2B while the stock rose 28% in twelve months.

  • WatchCapital spending down 44% to $16.2M in the latest quarter

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
13,000
Website
icumed.com
Listed
Nasdaq, US
Last results
5 Nov 2026
Next results
expected around 18 Feb 2027 (an estimate: a year ago it reported on 19 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $560.4M, net income $26.8M.
Quarter to 31 Mar 2022: revenue $543.1M, net income -$38.1MQuarter to 31 Mar 2022: revenue $543.1M, net income -$38.1MQuarter to 30 Jun 2022: revenue $561.0M, net income -$7.5MQuarter to 30 Jun 2022: revenue $561.0M, net income -$7.5MQuarter to 30 Sep 2022: revenue $597.9M, net income -$13.2MQuarter to 30 Sep 2022: revenue $597.9M, net income -$13.2MQuarter to 31 Mar 2023: revenue $568.6M, net income -$9.8MQuarter to 31 Mar 2023: revenue $568.6M, net income -$9.8MQuarter to 30 Jun 2023: revenue $549.3M, net income -$9.9MQuarter to 30 Jun 2023: revenue $549.3M, net income -$9.9MQuarter to 30 Sep 2023: revenue $553.3M, net income $7.2MQuarter to 30 Sep 2023: revenue $553.3M, net income $7.2MQuarter to 31 Mar 2024: revenue $566.7M, net income -$39.5MQuarter to 31 Mar 2024: revenue $566.7M, net income -$39.5MQuarter to 30 Jun 2024: revenue $596.5M, net income -$21.4MQuarter to 30 Jun 2024: revenue $596.5M, net income -$21.4MQuarter to 30 Sep 2024: revenue $589.1M, net income -$33.0MQuarter to 30 Sep 2024: revenue $589.1M, net income -$33.0MQuarter to 31 Mar 2025: revenue $604.7M, net income -$15.5MQuarter to 31 Mar 2025: revenue $604.7M, net income -$15.5MQuarter to 30 Jun 2025: revenue $548.9M, net income $35.3MQuarter to 30 Jun 2025: revenue $548.9M, net income $35.3MQuarter to 30 Sep 2025: revenue $537.0M, net income -$3.4MQuarter to 30 Sep 2025: revenue $537.0M, net income -$3.4MQuarter to 31 Mar 2026: revenue $530.2M, net income $30.1MQuarter to 31 Mar 2026: revenue $530.2M, net income $30.1MQuarter to 30 Jun 2026: revenue $551.7M, net income $19.1MQuarter to 30 Jun 2026: revenue $551.7M, net income $19.1MQuarter to 30 Sep 2026: revenue $560.4M, net income $26.8MQuarter to 30 Sep 2026: revenue $560.4M, net income $26.8M
31 Mar 2022RevenueNet incomeNet losstallest bar $604.7M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$560.4M$26.8M
30 Jun 2026$551.7M$19.1M
31 Mar 2026$530.2M$30.1M
30 Sep 2025$537.0M-$3.4M
30 Jun 2025$548.9M$35.3M
31 Mar 2025$604.7M-$15.5M
30 Sep 2024$589.1M-$33.0M
30 Jun 2024$596.5M-$21.4M
31 Mar 2024$566.7M-$39.5M
30 Sep 2023$553.3M$7.2M
30 Jun 2023$549.3M-$9.9M
31 Mar 2023$568.6M-$9.8M
30 Sep 2022$597.9M-$13.2M
30 Jun 2022$561.0M-$7.5M
31 Mar 2022$543.1M-$38.1M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $2.2B $2.3B
Revenue growthRevenue of the last 12 months compared with the 12 months before. -5.9% +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $60.3M -$7.4M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $2.40 -$0.32
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 40.3% 36.5% 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 5.1% 3.2% -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 2.8% -0.3% -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 2.8% -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $208.6M $72.0M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $301.8M $299.7M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $1.2B $1.3B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $850.1M $1.0B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.53 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $87.62
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 71.5 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 2.0 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 2.4 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 2.0 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
ICU MedicalICUI (this company) $4.3B71.52.0-5.9%2.8%
MiniMedMMED $4.5Bloss1.4–-9.6%
HeartflowHTFL $4.1Bloss17.2+47%-33.1%
Merit Medical SystemsMMSI $5.1B31.63.1+9.1%9.9%
HaemoneticsHAE $5.5B52.74.0+4.1%7.5%
Pulse BiosciencesPLSE $3.4Blossover 999+1637%–

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$4.0M

bought $0, sold $4.0M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+9.9%

311 13F filers vs 283

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

25.3M shares held by 13F filers (30 Sep 2026) of 25.0M outstanding (31 Oct 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

6.7%

1.7M shares sold short (30 Oct 2026) of 25.0M outstanding (31 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

8.0

1.7M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-2.4%

1.7M shares sold short in the report before, 1.7M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

69%

69% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 62%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

+8.0%

27 vs 25 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+4.4%

$560.4M vs $537.0M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-44%

$16.2M vs $29.1M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

25

25 articles in the last 7 days; its usual week has 1.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

17×

25 articles in the last 7 days; its usual week has 1.5.

Price $172.52 on 20 Nov 2026, +28% over 12 months (12-month range $115.45 to $187.26)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $8.0M in the last 12 months (the 12 months before: -$8.3M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 27 published in the last 12 months, +8.0% on the 12 months before.
Revenue per quarter. Revenue $560.4M in the latest quarter, +4.4% on a year earlier.
Capital spending per quarter. Capital spending $16.2M in the latest quarter, -44% on a year earlier.
Institutional holders (13F filers). 311 13F filers reported holding it in the latest 13F quarter, +21% on a year earlier.
Federal obligations. Federal obligations: $63K published in the last 12 months, +117% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
16 Jun 2026Sharp changeShort interest spike: short interest spike, 1.8M vs usual 1.3M (2026-05-29); 1.7x the same period a year earlier
20 Feb 20268-K and other filingsDirector or officer change
20 Feb 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 May 20258-K and other filingsDirector or officer change
14 May 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Oct 20248-K and other filingsDirector or officer change
2 Oct 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
29 Feb 20248-K and other filingsDirector or officer change
29 Feb 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
22 May 20238-K and other filingsDirector or officer change
22 May 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Feb 2023Sharp changeQuarterly revenue change: quarterly revenue change, 578.0M vs usual 338.3M (2022-12-31); 1.7x the same period a year earlier
3 Jan 20238-K and other filingsDirector or officer change
3 Jan 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
8 Nov 2022Sharp changeQuarterly revenue change: quarterly revenue change, 597.9M vs usual 328.9M (2022-09-30); 1.8x the same period a year earlier
11 Oct 2022Sharp changeFederal obligations jump: federal obligations jump, 5.5M vs usual 25K in the same month of earlier years (2022-09-01..2022-09-30); 19538.5x the same month a year earlier
6 Oct 2022Sharp changeFirst award from a new federal agency: first award from a new federal agency (General Services Administration): ICU MEDICAL SALES, INC.: new General Services Administration contract 47QSWC22C0001 ($5,453,000)
16 Aug 2022Sharp changeQuarterly revenue change: quarterly revenue change, 561.0M vs usual 321.1M (2022-06-30); 1.7x the same period a year earlier
10 May 2022Sharp changeQuarterly revenue change: quarterly revenue change, 543.1M vs usual 321.1M (2022-03-31); 1.7x the same period a year earlier
20 Apr 20228-K and other filingsDirector or officer change
18 Feb 20228-K and other filingsDirector or officer change
1 Feb 20228-K and other filingsDirector or officer change
7 Jan 20228-K and other filingsCompleted an acquisition or asset sale
4 Jan 20228-K and other filingsDirector or officer change
4 Jan 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: -$2.9M published
Month from 1 Mar 2022: -$8.6M published
Month from 1 May 2022: $4.3M published
Month from 1 Nov 2022: -$52K published
Month from 1 Feb 2023: -$346K published
Month from 1 Apr 2023: -$122K published
Month from 1 Jun 2023: -$5.7M published
Month from 1 Jul 2023: -$5.4M published
Month from 1 Sep 2023: -$884K published
Month from 1 Dec 2023: -$152K published
Month from 1 Mar 2024: -$183.5M published
Month from 1 May 2024: -$1.5M published
Month from 1 Aug 2024: -$2.6M published
Month from 1 Sep 2024: -$2.0M published
Month from 1 Oct 2024: -$2.1M published
Month from 1 Nov 2024: -$4.0M published
Month from 1 Dec 2024: -$2.3M published
Month from 1 Jan 2025: -$213K published
Month from 1 May 2025: -$7.7M published
Month from 1 Aug 2025: $2.6M published
Month from 1 Nov 2025: -$754K published
Month from 1 May 2026: -$882K published
Month from 1 Aug 2026: -$3.1M published
Month from 1 Sep 2026: -$3.5M published
Month from 1 Nov 2026: -$471K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 4 published
Quarter from 1 Apr 2022: 10 published
Quarter from 1 Jul 2022: 13 published
Quarter from 1 Oct 2022: 7 published
Quarter from 1 Jan 2023: 2 published
Quarter from 1 Apr 2023: 4 published
Quarter from 1 Jul 2023: 8 published
Quarter from 1 Oct 2023: 5 published
Quarter from 1 Jan 2024: 3 published
Quarter from 1 Apr 2024: 4 published
Quarter from 1 Jul 2024: 4 published
Quarter from 1 Oct 2024: 2 published
Quarter from 1 Jan 2025: 5 published
Quarter from 1 Apr 2025: 5 published
Quarter from 1 Jul 2025: 12 published
Quarter from 1 Oct 2025: 3 published
Quarter from 1 Jan 2026: 1 published
Quarter from 1 Apr 2026: 5 published
Quarter from 1 Jul 2026: 12 published
Quarter from 1 Oct 2026: 9 published
Revenue per quarter
Quarter ended 31 Mar 2022: $543.1M, +71% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $561.0M, +74% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $597.9M, +78% on a year earlier; public on 8 Nov 2022
Quarter ended 31 Mar 2023: $568.6M, +4.7% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $549.3M, -2.1% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $553.3M, -7.5% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Mar 2024: $566.7M, -0.4% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $596.5M, +8.6% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $589.1M, +6.5% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Mar 2025: $604.7M, +6.7% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $548.9M, -8.0% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $537.0M, -8.9% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Mar 2026: $530.2M, -12% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $551.7M, +0.5% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $560.4M, +4.4% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $22.1M, -26% on a year earlier; public on 26 Feb 2022
Quarter ended 31 Mar 2022: $23.6M, +68% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $24.4M, +56% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $20.7M, +23% on a year earlier; public on 8 Nov 2022
Quarter ended 31 Dec 2022: $21.6M, -2.2% on a year earlier; public on 28 Feb 2023
Quarter ended 31 Mar 2023: $14.2M, -40% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $18.3M, -25% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $21.5M, +3.8% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $29.9M, +39% on a year earlier; public on 28 Feb 2024
Quarter ended 31 Mar 2024: $15.9M, +12% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $19.5M, +6.5% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $19.9M, -7.3% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $24.1M, -20% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $14.6M, -8.1% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $19.7M, +1.2% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $29.1M, +46% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $24.6M, +2.3% on a year earlier; public on 20 Feb 2026
Quarter ended 31 Mar 2026: $11.3M, -23% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $18.5M, -6.0% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $16.2M, -44% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 263; public on 14 Feb 2022
31 Mar 2022 report: 274; public on 16 May 2022
30 Jun 2022 report: 241; public on 15 Aug 2022
30 Sep 2022 report: 218; public on 14 Nov 2022
31 Dec 2022 report: 222; public on 14 Feb 2023
31 Mar 2023 report: 216; public on 15 May 2023
30 Jun 2023 report: 210; public on 14 Aug 2023
30 Sep 2023 report: 201; public on 14 Nov 2023
31 Dec 2023 report: 227; public on 14 Feb 2024
31 Mar 2024 report: 239; public on 15 May 2024
30 Jun 2024 report: 241; public on 14 Aug 2024
30 Sep 2024 report: 272; public on 14 Nov 2024
31 Dec 2024 report: 281; public on 14 Feb 2025
31 Mar 2025 report: 270; public on 15 May 2025
30 Jun 2025 report: 264; public on 14 Aug 2025
30 Sep 2025 report: 258; public on 14 Nov 2025
31 Dec 2025 report: 279; public on 17 Feb 2026
31 Mar 2026 report: 267; public on 15 May 2026
30 Jun 2026 report: 283; public on 14 Aug 2026
30 Sep 2026 report: 311; public on 16 Nov 2026
Federal obligations
Month from 1 Dec 2021: $279 published
Month from 1 Jan 2022: $1K published
Month from 1 Feb 2022: $134K published
Month from 1 Mar 2022: $83K published
Month from 1 Apr 2022: $2K published
Month from 1 May 2022: $551K published
Month from 1 Jun 2022: $91K published
Month from 1 Aug 2022: $80.4 published
Month from 1 Sep 2022: $22K published
Month from 1 Oct 2022: $5.5M published
Month from 1 Nov 2022: -$5K published
Month from 1 Dec 2022: $498 published
Month from 1 Jan 2023: $159 published
Month from 1 Feb 2023: -$28K published
Month from 1 Mar 2023: $13K published
Month from 1 May 2023: $8K published
Month from 1 Jun 2023: $214K published
Month from 1 Jul 2023: -$743K published
Month from 1 Aug 2023: $185K published
Month from 1 Sep 2023: -$270 published
Month from 1 Oct 2023: $50K published
Month from 1 Apr 2024: $675 published
Month from 1 Jun 2024: $6K published
Month from 1 Nov 2024: $0 published
Month from 1 Jan 2025: -$6K published
Month from 1 May 2025: $34K published
Month from 1 Feb 2026: -$81.6 published
Month from 1 May 2026: -$14K published
Month from 1 Nov 2026: $77K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $156K (20 Nov 2026), 63% below its normal reading of $421K; higher than 17% of its own history.
  • Short interest spike: had 1.8M shares sold short in the 29 May 2026 report, 1.7× the same report last year Public on 10 Jun 2026.
  • Insider net buying (open market): Insiders sold a net $8.0M in the last 12 months (the 12 months before: -$8.3M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 27 published in the last 12 months, +8.0% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 5 sales, $4.0M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
20 Nov 2026David C. GreenbergDirectorSellafter exercising options883$176.12$156KForm 4
13 Nov 2026Elisha W FinneyDirectorSellafter exercising options1,765$179.00$316KForm 4
3 Sep 2026Virginia Ruth SanzoneVP, General CounselSellplanned in advance (10b5-1)4,856$168.69$819KForm 4
1 Sep 2026Brian Michael BonnellChief Financial OfficerSellplanned in advance (10b5-1)6,381$175.00$1.1MForm 4
31 Aug 2026Brian Michael BonnellChief Financial OfficerSellplanned in advance (10b5-1)9,307$172.79$1.6MForm 4
13 Aug 2026Daniel WoolsonVP, GM-Infusion CapitalSell5,417$181.33$982KForm 4
12 Aug 2026Ben SousaChief Information OfficerSell2,250$178.32$401KForm 4
11 Aug 2026Elisha W FinneyDirectorSell378$182.48$69KForm 4

311 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 47 opened a position, 23 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.3.7M15.0%$600.5M-12K-0.3%
Janus Henderson Group Ltd.2.8M11.0%$442.5M
Vanguard Portfolio Management LLC1.5M5.86%$235.4M-4,283-0.3%
Vanguard Capital Management LLC1.1M4.49%$180.4M+591+0.1%
Dimensional Fund Advisors LP1.1M4.38%$176.0M+43K+4.1%
Fuller & Thaler Asset Management, Inc.1.1M4.34%$174.3M-212K-16%
State Street Corp1.0M4.09%$164.1M-1,714-0.2%
Geode Capital Management, LLC657K2.63%$105.5M-3,443-0.5%
Citadel Advisors LLC608K2.43%$97.6M+72K+13%
Victory Capital Management Inc580K2.32%$93.1M+368K+174%

Federal contracts

All 2 federal contracts

No new award in 12 months; the latest was signed 30 Sep 2022. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
30 Sep 2022General Services AdministrationFederal Acquisition Service$5.5Mup to $7.7MVISN 12 LARGE VOLUME AND PCA SMART INFUSION PUMPSUSAspending
23 Apr 2020Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$3.2MHIGH ACUITY KIT (HAK) INFUSION PUMPS AND DISPOSABLES IN ACCORDANCE WITH ICU MEDICAL PROPOSAL DATED 4/3/2020, PUMPS SNS PROPOSAL HIGH ACUITY KIT - 300 BEDS.USAspending

Company events

All 35 company events

In 12 months: 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
20 Feb 2026Director or officer change8-K
14 May 2025Director or officer changeSame filing: shareholder vote results8-K
2 Oct 2024Director or officer change8-K
29 Feb 2024Director or officer change8-K
22 May 2023Director or officer changeSame filing: shareholder vote results8-K
3 Jan 2023Director or officer change8-K
20 Apr 2022Director or officer change8-K
18 Feb 2022Director or officer change8-K

Reported lobbying spend: $10K in Q1 2014, $20K in Q4 2013. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Dec 2014EndedOldaker Group, LLCfor Icu Medical IncNot statedFiling
10 Dec 2013NewOldaker Group, LLCfor Icu Medical IncMedical device marketing, promotion and taxationHealth issuesFiling

The 5 newest of 141 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

8 Nov 2022confirmed

Confirmed across sources Government contracts and Filings + Financials

ICU Medical (ICUI): booked $5.5M in federal contract and grant obligations in September 2022, 19,539× the same month last year, while it reported revenue of $597.9M for the quarter ended 30 Sep 2022, 1.8× the same quarter last year. Two unrelated kinds of activity within 28 days.

  • Government contracts: Federal obligations jump, became public on 6 Oct 2022
  • Financials: Quarterly revenue change, became public on 8 Nov 2022
2017-09-01: $70K2018-09-01: $25K2019-09-01: $33K2020-09-01: $16K2021-09-01: $2792022-09-01: $5.5M
September 2022 against the 5 months before it. this monthearliernormal: $25K
See the evidence (2 changes)

Government contracts: Federal obligations jump became public on 6 Oct 2022

ICU Medical booked $5.5M in federal contract and grant obligations in September 2022, 19,539× the same month last year.

This period
$5.5M (September 2022)
Normal month (median of 5 earlier)
$25K
Typical spread (median absolute deviation)
$9K
How far from its usual level
+5.4
Same month last year
$279
History used
5,461 days
2017-09-01: $70K2018-09-01: $25K2019-09-01: $33K2020-09-01: $16K2021-09-01: $2792022-09-01: $5.5M
September 20225 earlier monthsnormal: $25K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

Check it at the source: USAspending.gov award search.

Financials: Quarterly revenue change became public on 8 Nov 2022

ICU Medical reported revenue of $597.9M for the quarter ended 30 Sep 2022, 1.8× the same quarter last year.

This period
$597.9M (the quarter ended 30 Sep 2022)
Normal quarter (median of 8 earlier)
$328.9M
Typical spread (median absolute deviation)
$10.6M
How far from its usual level
+8.2
Same quarter last year
$336.1M
History used
5,296 days
2020-09-30: $318.6M2020-12-31: $320.5M2021-03-31: $318.0M2021-06-30: $321.7M2021-09-30: $336.1M2021-12-31: $340.5M2022-03-31: $543.1M2022-06-30: $561.0M2022-09-30: $597.9M
the quarter ended 30 Sep 20228 earlier quartersnormal: $328.9M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 10 Jun 2026Short interest and volume change

    had 1.8M shares sold short in the 29 May 2026 report, 1.7× the same report last year.

    Same report last year: 1.1M; its normal report is 1.3M.

    See the evidence
    This period
    1.8M (the 29 May 2026 report)
    Normal report (median of 24 earlier)
    1.3M
    Typical spread (median absolute deviation)
    89K
    How far from its usual level
    +4.1
    Same report last year
    1.1M
    History used
    3,073 days
    2025-05-30: 1.1M2025-06-13: 1.1M2025-06-30: 1.4M2025-07-15: 1.2M2025-07-31: 1.3M2025-08-15: 1.2M2025-08-29: 1.4M2025-09-15: 1.5M2025-09-30: 1.4M2025-10-15: 1.3M2025-10-31: 1.5M2025-11-14: 1.3M2025-11-28: 1.3M2025-12-15: 1.3M2025-12-31: 1.2M2026-01-15: 1.1M2026-01-30: 1.1M2026-02-13: 1.0M2026-02-27: 1.1M2026-03-13: 1.2M2026-03-31: 1.3M2026-04-15: 1.3M2026-04-30: 1.6M2026-05-15: 1.6M2026-05-29: 1.8M
    the 29 May 2026 report24 earlier reportsnormal: 1.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  2. 20 Feb 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  3. 20 Feb 2026Filings record

    Director or officer change

  4. 28 Aug 2025Insiders record

    Greenberg David C. (director) bought 1,200 shares of ICUI ($151,697) (dated 27 Aug 2025)

  5. 15 Aug 2025Insiders record

    Jain Vivek (Chairman and CEO) bought 21,929 shares of ICUI ($2.5M) (dated 14 Aug 2025)

  6. 14 May 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  7. 14 May 2025Filings record

    Director or officer change

  8. 2 Oct 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  9. 2 Oct 2024Filings record

    Director or officer change

  10. 29 Feb 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  11. 29 Feb 2024Filings record

    Director or officer change

  12. 22 May 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  13. 22 May 2023Filings record

    Director or officer change

  14. 28 Feb 2023Financials change

    reported revenue of $578.0M for the quarter ended 31 Dec 2022, 1.7× the same quarter last year.

    Same quarter last year: $340.5M; its normal quarter is $338.3M.

    See the evidence
    This period
    $578.0M (the quarter ended 31 Dec 2022)
    Normal quarter (median of 8 earlier)
    $338.3M
    Typical spread (median absolute deviation)
    $19.0M
    How far from its usual level
    +7.1
    Same quarter last year
    $340.5M
    History used
    5,388 days
    2020-12-31: $320.5M2021-03-31: $318.0M2021-06-30: $321.7M2021-09-30: $336.1M2021-12-31: $340.5M2022-03-31: $543.1M2022-06-30: $561.0M2022-09-30: $597.9M2022-12-31: $578.0M
    the quarter ended 31 Dec 20228 earlier quartersnormal: $338.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  15. 3 Jan 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  16. 3 Jan 2023Filings record

    Director or officer change

  17. 8 Nov 2022several at once

    booked $5.5M in federal contract and grant obligations in September 2022, 19,539× the same month last year, while it reported revenue of $597.9M for the quarter ended 30 Sep 2022, 1.8× the same quarter last year. Two unrelated kinds of activity within 28 days.

    See the evidence (2 changes)

    Government contracts: Federal obligations jump became public on 6 Oct 2022

    ICU Medical booked $5.5M in federal contract and grant obligations in September 2022, 19,539× the same month last year.

    This period
    $5.5M (September 2022)
    Normal month (median of 5 earlier)
    $25K
    Typical spread (median absolute deviation)
    $9K
    How far from its usual level
    +5.4
    Same month last year
    $279
    History used
    5,461 days
    2017-09-01: $70K2018-09-01: $25K2019-09-01: $33K2020-09-01: $16K2021-09-01: $2792022-09-01: $5.5M
    September 20225 earlier monthsnormal: $25K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

    Check it at the source: USAspending.gov award search.

    Financials: Quarterly revenue change became public on 8 Nov 2022

    ICU Medical reported revenue of $597.9M for the quarter ended 30 Sep 2022, 1.8× the same quarter last year.

    This period
    $597.9M (the quarter ended 30 Sep 2022)
    Normal quarter (median of 8 earlier)
    $328.9M
    Typical spread (median absolute deviation)
    $10.6M
    How far from its usual level
    +8.2
    Same quarter last year
    $336.1M
    History used
    5,296 days
    2020-09-30: $318.6M2020-12-31: $320.5M2021-03-31: $318.0M2021-06-30: $321.7M2021-09-30: $336.1M2021-12-31: $340.5M2022-03-31: $543.1M2022-06-30: $561.0M2022-09-30: $597.9M
    the quarter ended 30 Sep 20228 earlier quartersnormal: $328.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  18. 8 Nov 2022Financials change

    reported revenue of $597.9M for the quarter ended 30 Sep 2022, 1.8× the same quarter last year.

    Same quarter last year: $336.1M; its normal quarter is $328.9M.

    See the evidence
    This period
    $597.9M (the quarter ended 30 Sep 2022)
    Normal quarter (median of 8 earlier)
    $328.9M
    Typical spread (median absolute deviation)
    $10.6M
    How far from its usual level
    +8.2
    Same quarter last year
    $336.1M
    History used
    5,296 days
    2020-09-30: $318.6M2020-12-31: $320.5M2021-03-31: $318.0M2021-06-30: $321.7M2021-09-30: $336.1M2021-12-31: $340.5M2022-03-31: $543.1M2022-06-30: $561.0M2022-09-30: $597.9M
    the quarter ended 30 Sep 20228 earlier quartersnormal: $328.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  19. 6 Oct 2022Government contracts change

    booked $5.5M in federal contract and grant obligations in September 2022, 19,539× the same month last year.

    Same month last year: $279; its normal month is $25K.

    See the evidence
    This period
    $5.5M (September 2022)
    Normal month (median of 5 earlier)
    $25K
    Typical spread (median absolute deviation)
    $9K
    How far from its usual level
    +5.4
    Same month last year
    $279
    History used
    5,461 days
    2017-09-01: $70K2018-09-01: $25K2019-09-01: $33K2020-09-01: $16K2021-09-01: $2792022-09-01: $5.5M
    September 20225 earlier monthsnormal: $25K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

    Check it at the source: USAspending.gov award search.

  20. 6 Oct 2022Government contracts change

    won its first award from the General Services Administration, a $5.5M contract, after 1 earlier federal award from other agencies.

    See the evidence (1 source record)
    Source coverage starts
    7 Oct 2007
    Earlier events of other kinds
    1

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  21. 6 Oct 2022Government contracts record

    ICU MEDICAL SALES, INC.: new General Services Administration contract 47QSWC22C0001 ($5.5M) (dated 30 Sep 2022)

  22. 16 Aug 2022Financials change

    reported revenue of $561.0M for the quarter ended 30 Jun 2022, 1.7× the same quarter last year.

    Same quarter last year: $321.7M; its normal quarter is $321.1M.

    See the evidence
    This period
    $561.0M (the quarter ended 30 Jun 2022)
    Normal quarter (median of 8 earlier)
    $321.1M
    Typical spread (median absolute deviation)
    $9.0M
    How far from its usual level
    +7.5
    Same quarter last year
    $321.7M
    History used
    5,204 days
    2020-06-30: $303.4M2020-09-30: $318.6M2020-12-31: $320.5M2021-03-31: $318.0M2021-06-30: $321.7M2021-09-30: $336.1M2021-12-31: $340.5M2022-03-31: $543.1M2022-06-30: $561.0M
    the quarter ended 30 Jun 20228 earlier quartersnormal: $321.1M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  23. 14 May 2022Insiders record

    LOPEZ GEORGE A (director) bought 25,835 shares of ICUI ($4.5M) (dated 13 May 2022)

  24. 10 May 2022Financials change

    reported revenue of $543.1M for the quarter ended 31 Mar 2022, 1.7× the same quarter last year.

    Same quarter last year: $318.0M; its normal quarter is $321.1M.

    See the evidence
    This period
    $543.1M (the quarter ended 31 Mar 2022)
    Normal quarter (median of 8 earlier)
    $321.1M
    Typical spread (median absolute deviation)
    $5.3M
    How far from its usual level
    +6.9
    Same quarter last year
    $318.0M
    History used
    5,113 days
    2020-03-31: $328.6M2020-06-30: $303.4M2020-09-30: $318.6M2020-12-31: $320.5M2021-03-31: $318.0M2021-06-30: $321.7M2021-09-30: $336.1M2021-12-31: $340.5M2022-03-31: $543.1M
    the quarter ended 31 Mar 20228 earlier quartersnormal: $321.1M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  25. 20 Apr 2022Filings record

    Director or officer change

  26. 18 Feb 2022Filings record

    Director or officer change

  27. 1 Feb 2022Filings record

    Director or officer change

  28. 7 Jan 2022Filings record

    Completed an acquisition or asset sale

  29. 4 Jan 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  30. 4 Jan 2022Filings record

    Director or officer change

  31. 11 Aug 2021Short interest and volume change

    had 706K shares sold short in the 30 Jul 2021 report, 2.9× the same report last year.

    Same report last year: 243K; its normal report is 317K.

    See the evidence
    This period
    706K (the 30 Jul 2021 report)
    Normal report (median of 24 earlier)
    317K
    Typical spread (median absolute deviation)
    56K
    How far from its usual level
    +4.7
    Same report last year
    243K
    History used
    1,309 days
    2020-07-31: 243K2020-08-14: 276K2020-08-31: 277K2020-09-15: 299K2020-09-30: 262K2020-10-15: 275K2020-10-30: 260K2020-11-13: 263K2020-11-30: 303K2020-12-15: 313K2020-12-31: 465K2021-01-15: 320K2021-01-29: 276K2021-02-12: 291K2021-02-26: 332K2021-03-15: 426K2021-03-31: 429K2021-04-15: 459K2021-04-30: 471K2021-05-14: 441K2021-05-28: 410K2021-06-15: 415K2021-06-30: 472K2021-07-15: 553K2021-07-30: 706K
    the 30 Jul 2021 report24 earlier reportsnormal: 317K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  32. 27 Jul 2021Short interest and volume change

    had 553K shares sold short in the 15 Jul 2021 report, 2.0× the same report last year.

    Same report last year: 270K; its normal report is 308K.

    See the evidence
    This period
    553K (the 15 Jul 2021 report)
    Normal report (median of 24 earlier)
    308K
    Typical spread (median absolute deviation)
    45K
    How far from its usual level
    +3.7
    Same report last year
    270K
    History used
    1,294 days
    2020-07-15: 270K2020-07-31: 243K2020-08-14: 276K2020-08-31: 277K2020-09-15: 299K2020-09-30: 262K2020-10-15: 275K2020-10-30: 260K2020-11-13: 263K2020-11-30: 303K2020-12-15: 313K2020-12-31: 465K2021-01-15: 320K2021-01-29: 276K2021-02-12: 291K2021-02-26: 332K2021-03-15: 426K2021-03-31: 429K2021-04-15: 459K2021-04-30: 471K2021-05-14: 441K2021-05-28: 410K2021-06-15: 415K2021-06-30: 472K2021-07-15: 553K
    the 15 Jul 2021 report24 earlier reportsnormal: 308K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 7 Jul 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  34. 7 Jul 2021Filings record

    Director or officer change

  35. 29 Apr 2020Government contracts change

    won its first federal award in our data, a $3.2M Department of Health and Human Services contract.

    See the evidence (1 source record)
    Source coverage starts
    7 Oct 2007
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  36. 29 Apr 2020Government contracts record

    ICU MEDICAL, INC.: new Department of Health and Human Services contract 75A50120C00089 ($3.2M) (dated 23 Apr 2020)

  37. 28 Feb 2020Filings record

    Director or officer change

  38. 6 Jan 2020Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  39. 6 Jan 2020Filings record

    Director or officer change

  40. 8 Jul 2019Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

Showing the newest 40 of 60 entries; narrow the window or the kind of data to see older ones.

Not listed: 278 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000883984
Ticker
ICUI
Domain
icumed.com
Employer name
ICU Medical, Inc., ICU Medical Sales, Inc. (2 unverified)
Fein
06-1211921 (1 unverified)
Hq location
CA|SAN CLEMENTE|92763 (1 unverified)
Lobbying client
icu medical
Name
Excelsior Medical Corporation, EXC Holding Corp, ICU Medical 2020 Limited, ICU Medical Argentina S.R.L and 59 more
Uei
G2WSBX6JWKB5, MKGHE5M8ANQ7
Wikidata
Q5969799
Wikipedia
ICU Medical
  • DOL H-1B labor condition applications and PERM certifications630 data points7 Oct 2019 to 28 Sep 2026
  • Federal lobbying disclosures (LDA)2 records, 12 data points10 Dec 2013 to 31 Dec 2014
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)132 records11 Jan 2016 to 5 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1334 data points31 Dec 2006 to 31 Oct 2026
  • SEC Form 4 insider transactions180 records, 644 data points5 Jan 2016 to 20 Nov 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards2 records, 1341 data points18 Oct 2007 to 25 Sep 2026
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026